DRRX DURECT Corporation

0.90
+0  (2%)
Previous Close 0.88
Open 0.88
Price To book 14.92
Market Cap 127.02M
Shares 141,892,000
Volume 285,919
Short Ratio 6.89
Av. Daily Volume 317,560

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial likely to be initiated in 2017.
DUR-928
Primary sclerosing cholangitis (PSC)
CRL issued February 12, 2014.
Posidur
Post-operative pain relief
CRL Feb 12 2014. Phase 3 commenced November 2015 in response to CRL. Enrollment originally expected to take one year but the company announced amendments to the trial on April 7, 2016, which will result in time added to complete the trial. Part 2 of the Phase 3 trial is expected to complete enrollment around 3Q 2017 with top-line data by the end of 2017.
POSIMIR - PERSIST 3
Post-operative pain relief
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Phase 1b dosing progressed to higher dosage - announced October 31, 2016. Update January 30, 2017 noted one possible treatment related adverse event.
DUR-928
Nonalcoholic steatohepatitis (NASH)
CRL issued September 26, 2016. Noted March 20, 2017 that it intends to resubmit the NDA following additional trials to be completed by the end of 2017.
Remoxy
Chronic pain

Latest News

  1. DURECT to Present Clinical Data at the International Liver Congress™ 2017
  2. DURECT to Present at the H.C. Wainwright NASH Investor Conference
  3. The Life Sciences Report Interviews DURECT Corp. President and CEO James Brown
  4. ETFs with exposure to DURECT Corp. : March 27, 2017
  5. DURECT Corp. :DRRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  6. How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma
  7. Durect reports 4Q loss
  8. DURECT Corporation Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs
  9. DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference Call
  10. DRRX: Update on DUR-928 Development Program
  11. DURECT Corporation Announces Update on DUR-928 Development Program
  12. How DURECT Corporation (DRRX) Stacks Up Against Its Peers
  13. ETFs with exposure to DURECT Corp. : December 9, 2016
  14. ETF’s with exposure to DURECT Corp. : November 3, 2016
  15. The Life Sciences Report Examines Why the Election Is Not as Relevant to Drug Stocks as You Might Believe
  16. DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 2, 2016
  17. Durect (DRRX) Exited Third Quarter with Strong Balance Sheet
  18. DURECT Corporation Invites You to Join its Third Quarter 2016 Earnings Conference Call